AAAAAA

   
Results: 1-10 |
Results: 10
A RANDOMIZED STUDY OF SRL172 (MYCOBACTERIUM VACCAE) IN PATIENTS WITH ADVANCED LUNG-CANCER TREATED WITH CHEMOTHERAPY
Authors: WEBB A ALMOUNDHRI M SOUBERBIELLE BE NORTON A PRIEST K RYAN C MENDES R ASHLEY S SMITH IE OBRIEN MER
Citation: A. Webb et al., A RANDOMIZED STUDY OF SRL172 (MYCOBACTERIUM VACCAE) IN PATIENTS WITH ADVANCED LUNG-CANCER TREATED WITH CHEMOTHERAPY, Annals of oncology, 9, 1998, pp. 421-421
GOOD SYMPTOM RELIEF WITH PALLIATIVE MVP (MITOMYCIN-C, VINBLASTINE ANDCISPLATIN) CHEMOTHERAPY IN MALIGNANT MESOTHELIOMA
Authors: MIDDLETON GW SMITH IE OBRIEN MER NORTON A HICKISH T PRIEST K SPENCER L ASHLEY S
Citation: Gw. Middleton et al., GOOD SYMPTOM RELIEF WITH PALLIATIVE MVP (MITOMYCIN-C, VINBLASTINE ANDCISPLATIN) CHEMOTHERAPY IN MALIGNANT MESOTHELIOMA, Annals of oncology, 9(3), 1998, pp. 269-273
A RANDOMIZED STUDY OF SRL172 (MYCOBACTERIUM-VACCAE) IN PATIENTS WITH ADVANCED LUNG-CANCER TREATED WITH CHEMOTHERAPY
Authors: WEBB A ALMOUNDHRI M SOUBERBIELLE BE NORTON A PRIEST K RYAN C MENDES R ASHLEY S SMITH IE OBRIEN MER
Citation: A. Webb et al., A RANDOMIZED STUDY OF SRL172 (MYCOBACTERIUM-VACCAE) IN PATIENTS WITH ADVANCED LUNG-CANCER TREATED WITH CHEMOTHERAPY, British Journal of Cancer, 78, 1998, pp. 5-5
PHASE-I STUDY OF THE BIODISTRIBUTION, PHARMACOKINETICS AND IMMUNOGENICITY OF IN-111-HCTMO1 (CDP671)+ - PREDOSING WITH UNLABELED HCTMO1 IN PATIENTS (PTS) WITH LUNG-CANCER/
Authors: VERRILL M MIDDLETON G PRIEST K SPENCER L CHITTENDEN S MCCREADY R COX N SKELTON L OBRIEN M SMITH I
Citation: M. Verrill et al., PHASE-I STUDY OF THE BIODISTRIBUTION, PHARMACOKINETICS AND IMMUNOGENICITY OF IN-111-HCTMO1 (CDP671)+ - PREDOSING WITH UNLABELED HCTMO1 IN PATIENTS (PTS) WITH LUNG-CANCER/, European journal of cancer, 33, 1997, pp. 1114-1114
PHASE-I TRIAL AND TUMOR-LOCALIZATION OF THE ANTI-EGFR MONOCLONAL-ANTIBODY ICR62 IN HEAD AND NECK OR LUNG-CANCER
Authors: MODJTAHEDI H HICKISH T NICOLSON M MOORE J STYLES J ECCLES S JACKSON E SALTER J SLOANE J SPENCER L PRIEST K SMITH I DEAN C GORE M
Citation: H. Modjtahedi et al., PHASE-I TRIAL AND TUMOR-LOCALIZATION OF THE ANTI-EGFR MONOCLONAL-ANTIBODY ICR62 IN HEAD AND NECK OR LUNG-CANCER, British Journal of Cancer, 73(2), 1996, pp. 228-235
PERINATAL-MORTALITY TRENDS AMONG SOUTH AUSTRALIAN ABORIGINAL BIRTHS 1981-92
Authors: RODER D CHAN A PRIEST K
Citation: D. Roder et al., PERINATAL-MORTALITY TRENDS AMONG SOUTH AUSTRALIAN ABORIGINAL BIRTHS 1981-92, Journal of paediatrics and child health, 31(5), 1995, pp. 446-450
MVP (MITOMYCIN-C, VINBLASTINE AND CISPLATIN) CHEMOTHERAPY IN SMALL-CELL LUNG-CANCER (SCLC)
Authors: HICKISH TF SMITH IE NICOLSON MC PRIEST K SPENCER L ASHLEY S NORMAN A MIDDLETON G
Citation: Tf. Hickish et al., MVP (MITOMYCIN-C, VINBLASTINE AND CISPLATIN) CHEMOTHERAPY IN SMALL-CELL LUNG-CANCER (SCLC), European journal of cancer, 31A, 1995, pp. 88-88
DOSE INTENSIFICATION OF CARBOPLATIN AND ETOPOSIDE AS FIRST-LINE COMBINATION CHEMOTHERAPY IN SMALL-CELL LUNG-CANCER
Authors: ELLIS PA TALBOT DC PRIEST K JONES AL SMITH IE
Citation: Pa. Ellis et al., DOSE INTENSIFICATION OF CARBOPLATIN AND ETOPOSIDE AS FIRST-LINE COMBINATION CHEMOTHERAPY IN SMALL-CELL LUNG-CANCER, European journal of cancer, 31A(11), 1995, pp. 1888-1889
A PILOT-STUDY OF MITOMYCIN, CISPLATIN AND CONTINUOUS-INFUSION 5-FLUOROURACIL (MCF) IN ADVANCED NON-SMALL-CELL LUNG-CANCER
Authors: ELLIS PA TALBOT DC NICOLSON MC PRIEST K ASHLEY S SMITH IE
Citation: Pa. Ellis et al., A PILOT-STUDY OF MITOMYCIN, CISPLATIN AND CONTINUOUS-INFUSION 5-FLUOROURACIL (MCF) IN ADVANCED NON-SMALL-CELL LUNG-CANCER, British Journal of Cancer, 71(6), 1995, pp. 1315-1318
SYMPTOM RELIEF WITH MVP (MITOMYCIN-C, VINBLASTINE AND CISPLATIN) CHEMOTHERAPY IN ADVANCED NON-SMALL-CELL LUNG-CANCER
Authors: ELLIS PA SMITH IE HARDY JR NICOLSON MC TALBOT DC ASHLEY SE PRIEST K
Citation: Pa. Ellis et al., SYMPTOM RELIEF WITH MVP (MITOMYCIN-C, VINBLASTINE AND CISPLATIN) CHEMOTHERAPY IN ADVANCED NON-SMALL-CELL LUNG-CANCER, British Journal of Cancer, 71(2), 1995, pp. 366-370
Risultati: 1-10 |